Victory Capital Management Inc Tcr2 Therapeutics Inc. Transaction History

Victory Capital Management Inc

  • $99 Billion
  • Q3 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 09, 2023
SELL
$0.83 - $1.44 $8,254 - $14,320
-9,945 Reduced 11.81%
74,297 $74,000
Q3 2022

Nov 02, 2022
SELL
$1.86 - $3.75 $2,948 - $5,943
-1,585 Reduced 1.85%
84,242 $152,000
Q2 2022

Aug 01, 2022
BUY
$2.11 - $2.94 $2,183 - $3,042
1,035 Added 1.22%
85,827 $249,000
Q1 2022

May 04, 2022
BUY
$2.4 - $4.71 $924 - $1,813
385 Added 0.46%
84,792 $181,000
Q4 2021

Feb 07, 2022
SELL
$4.58 - $8.34 $59,567 - $108,470
-13,006 Reduced 13.35%
84,407 $393,000
Q3 2021

Nov 02, 2021
SELL
$8.44 - $18.35 $357,239 - $776,700
-42,327 Reduced 30.29%
97,413 $829,000
Q2 2021

Aug 03, 2021
SELL
$16.41 - $24.71 $17.9 Million - $27 Million
-1,091,660 Reduced 88.65%
139,740 $2.29 Million
Q1 2021

May 04, 2021
BUY
$20.38 - $34.07 $20.8 Million - $34.8 Million
1,022,384 Added 489.14%
1,231,400 $27.2 Million
Q4 2020

Feb 01, 2021
BUY
$19.0 - $32.63 $1.35 Million - $2.32 Million
71,251 Added 51.72%
209,016 $6.47 Million
Q3 2020

Nov 09, 2020
BUY
$13.1 - $20.69 $710,884 - $1.12 Million
54,266 Added 64.99%
137,765 $2.8 Million
Q2 2020

Aug 07, 2020
SELL
$6.51 - $16.85 $4,830 - $12,502
-742 Reduced 0.88%
83,499 $1.28 Million
Q1 2020

May 04, 2020
SELL
$6.01 - $16.01 $13,167 - $35,077
-2,191 Reduced 2.53%
84,241 $652,000
Q4 2019

Feb 06, 2020
BUY
$12.17 - $17.88 $21,467 - $31,540
1,764 Added 2.08%
86,432 $1.23 Million
Q4 2019

Feb 04, 2020
BUY
$12.17 - $17.88 $873,976 - $1.28 Million
71,814 Added 558.69%
84,668 $1.24 Million
Q3 2019

Nov 12, 2019
BUY
$10.15 - $19.53 $18,818 - $36,208
1,854 Added 16.85%
12,854 $193,000
Q1 2019

May 03, 2019
BUY
$15.01 - $22.15 $165,110 - $243,649
11,000 New
11,000 $192,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email